Sandy, UT – According to filings with the U.S. Securities and Exchange Commission, SignPath Pharma is raising $10,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kai Larson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About SignPath Pharma

Signpath Pharma is headquartered in Sandy, Utah (a suburb of Salt Lake City.) We have partnerships and working relationships with labs, hospitals, and other companies in Canada, Europe, the U.S., and Asia. Established in 2007 with the goal of developing Curcumin for cancer treatment, Signpath has since expanded into the area of cardiology, specifically the mitigation of pharmaceutical cardiac side effects. We are committed to bringing innovative new treatments through the clinic and into the marketplace, addressing significant unmet medical needs.

To learn more about SignPath Pharma, visit http://signpathpharma.com/

Contact:
Kai Larson, Chief Executive Officer
801-245-0313
https://www.linkedin.com/in/kai-larson-1329649/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved